Thurston Springer Miller Herd & Titak Inc. Has $164,000 Position in Novartis AG (NYSE:NVS)

Thurston Springer Miller Herd & Titak Inc. grew its holdings in shares of Novartis AG (NYSE:NVS) by 176.3% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 1,688 shares of the company’s stock after purchasing an additional 1,077 shares during the period. Thurston Springer Miller Herd & Titak Inc.’s holdings in Novartis were worth $164,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Legacy Investment Solutions LLC acquired a new position in Novartis during the third quarter valued at approximately $28,000. Richardson Financial Services Inc. bought a new position in shares of Novartis in the second quarter valued at $30,000. Fortitude Family Office LLC increased its holdings in Novartis by 503.8% during the third quarter. Fortitude Family Office LLC now owns 320 shares of the company’s stock worth $37,000 after buying an additional 267 shares during the last quarter. Clean Yield Group bought a new stake in Novartis during the third quarter worth $43,000. Finally, Versant Capital Management Inc lifted its stake in Novartis by 782.0% in the fourth quarter. Versant Capital Management Inc now owns 785 shares of the company’s stock valued at $76,000 after acquiring an additional 696 shares during the last quarter. 13.12% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on NVS. HSBC cut Novartis from a “hold” rating to a “reduce” rating in a report on Wednesday, December 4th. Erste Group Bank reaffirmed a “hold” rating on shares of Novartis in a report on Tuesday, November 19th. Finally, BMO Capital Markets lifted their price objective on shares of Novartis from $118.00 to $120.00 and gave the stock a “market perform” rating in a research report on Wednesday, October 30th. Two investment analysts have rated the stock with a sell rating and seven have given a hold rating to the company. According to MarketBeat.com, Novartis presently has a consensus rating of “Hold” and a consensus target price of $121.50.

Novartis Stock Down 1.4 %

Shares of NVS opened at $97.73 on Friday. The stock has a market capitalization of $199.76 billion, a price-to-earnings ratio of 11.35, a PEG ratio of 1.36 and a beta of 0.57. Novartis AG has a 52 week low of $92.35 and a 52 week high of $120.92. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.90 and a current ratio of 1.11. The stock has a fifty day moving average of $100.97 and a 200-day moving average of $109.12.

Novartis (NYSE:NVS) last released its quarterly earnings results on Tuesday, October 29th. The company reported $2.06 earnings per share for the quarter, topping the consensus estimate of $1.94 by $0.12. The company had revenue of $12.82 billion for the quarter, compared to analysts’ expectations of $12.62 billion. Novartis had a return on equity of 34.80% and a net margin of 35.96%. During the same period in the previous year, the business posted $1.74 earnings per share. As a group, sell-side analysts anticipate that Novartis AG will post 7.63 earnings per share for the current fiscal year.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.